Biointron, a Chinese contract research organisation (CRO) that serves life science researchers and biopharmaceutical companies, has secured almost 500 million yuan ($72.4 million) in a Series B funding round to expand its operations.
Biointron, which specialises in the provision of recombinant protein and antibody reagents, raised the funding from a wide range of Chinese domestic investors including CoStone Capital, Jifeng Ventures, Tenykin, and Haitong Securities’ venture capital (VC) arm, the startup announced in a statement on Wednesday.
